BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Cell Therapy » CAR-T » Page 2

Onk Therapeutics Secures $21.5M Series A for Cord Blood and iPSC-derived NK Cell therapies

January 17, 2022 By Cade Hildreth (CEO) Leave a Comment

ONK Therapeutics
  • $21.5M Series A financing round to advance pipeline of next-gen engineered off-the-shelf NK cell therapies
  • Funding round led by current investors Acorn Bioventures and ALSHC; joined by new investor Cormorant Asset Management
  • Financing will drive multiple pre-clinical programs through IND-enabling studies and the continued progression of a GMP manufacturing capability

[Read more…]

Filed Under: CAR-T, Cell Therapy, Cord Blood, iPS Cells

History of CAR-T Cell Therapy Spans 60+ Years

January 17, 2022 By Cade Hildreth (CEO) 1 Comment

history of car-t cell

The groundbreaking approvals of two CAR-T therapies in 2017 was the climax of more than sixty years of devoted research. In the 1950s, the discovery of bone marrow transplantation laid the foundation for developing CAR-T therapy, as it was the first time that living cells were infused into blood cancer patients for the control of cancer.

As early as 1900s, researchers were becoming aware that T cells could easily search, recognize and kill cancer cells. To do this, the cells need a “guide” to direct them to the tumors, and thus, antibodies emerged as a valuable scientific and medical tool. [Read more…]

Filed Under: CAR-T Tagged With: CAR-T

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

January 15, 2022 By Cade Hildreth (CEO) 5 Comments

CAR-T Companies

CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer.  This article provides a comprehensive list of CAR-T therapy companies worldwide. Read on to learn more about innovative CAR-T cell therapy companies and the technologies they are using to fight cancer.

In this article: 

    1. An Introduction to CAR-T Companies
    2. Chimeric Antigen Receptors
    3. Increase in CAR-T Biotech Companies
    4. List of CAR-T Cell Therapy Companies
    5. Swell of CAR-T Companies

[Read more…]

Filed Under: CAR-T, Cell Therapy Tagged With: CAR-T

CAR-T Cell Therapeutics: A Multi-Billion Dollar Market

December 5, 2021 By Cade Hildreth (CEO) Leave a Comment

CAR-T Cell Therapeutics

CAR-T is a promising type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the capacity to recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”

Since the approval of the first CAR-T cell therapeutic in 2017, widespread research, proliferating clinical trials, aggressive M&A activity, and lucrative IPOs have created a robust CAR-T cell market. [Read more…]

Filed Under: CAR-T

The State of CAR-T Cell Therapies in 2021

November 11, 2021 By Cade Hildreth (CEO) Leave a Comment

CAR-T cell therapies

Scientific progress within the field of cancer immunotherapy has led to five CAR-T cell therapy approvals: Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), and Abecma (idecabtagene vicleucel). Additionally, JW Therapeutics has announced NMPA approval of Relmacabtagene Autoleucel Injection in China. This is the first CAR-T product independently developed in China and approved as a Category 1 biologics product, as well as the sixth approved CAR-T product globally. [Read more…]

Filed Under: CAR-T, Cell Therapy

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 11
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97

Featured Posts

PolarityTE RMAT

PolarityTE Announces FDA RMAT Awarded to Its Designation Granted to SkinTE®

Advanced Therapy | What is a RMAT Designation (and Who Has One)?

What Is An RMAT? List of Publicly Announced RMAT Designations (64)

i-peaces-cell-manufacturing

I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.